← back to search

Maxine Tran

The Royal Free Hospital ·
Area of research
Pulmonary and Respiratory Medicine · Molecular Biology
Research interest
Research interests include Renal cell carcinoma treatment, Renal and related cancers, Bladder and Urothelial Cancer Treatments, and Cancer Genomics and Diagnostics.
h-index
30
citations
6,919
works
184
NIH funding
primary concept
Medicine
email

Recent publications

European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
European Urology 2025cited by 186position: middledoi
Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors
European Urology 2025cited by 42position: middledoi
Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitors and Subsequent Therapy for Renal Cell Carcinoma
European Urology 2025cited by 23position: middledoi
Fumarate induces vesicular release of mtDNA to drive innate immunity
Nature 2023cited by 301position: middledoi
Targetable NOTCH1 rearrangements in reninoma
Nature Communications 2023cited by 12position: middledoi
Interactive virtual 3D models of renal cancer patient anatomies alter partial nephrectomy surgical planning decisions and increase surgeon confidence compared to volume-rendered images
International Journal of Computer Assisted Radiology and Surgery 2019cited by 50position: middledoi
Independence of HIF1a and androgen signaling pathways in prostate cancer
bioRxiv (Cold Spring Harbor Laboratory) 2019cited by 2position: firstdoi
Development of a Disease-Specific Ureteral Calculus Patient Reported Outcome Measurement Instrument
Journal of Endourology 2018cited by 24position: firstdoi
Clinical and Molecular Features of Renal and Pheochromocytoma/Paraganglioma Tumor Association Syndrome (RAPTAS): Case Series and Literature Review
The Journal of Clinical Endocrinology & Metabolism 2017cited by 43position: middledoi
Fumarate is an epigenetic modifier that elicits epithelial-to-mesenchymal transition
Nature 2016cited by 575position: middledoi
A glycolytic phenotype is associated with prostate cancer progression and aggressiveness: a role for monocarboxylate transporters as metabolic targets for therapy
The Journal of Pathology 2015cited by 131position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Axel Bex · Dutch Cancer Society4 papers (2019–2025)Anne Y. Warren · University of Cambridge3 papers (2016–2019)Riccardo Campi · Virginia Commonwealth University3 papers (2025–2025)Grant D. Stewart · University of Cambridge2 papers (2017–2025)Jens Bedke · Medical University of Vienna2 papers (2025–2025)Thomas Powles · St Bartholomew's Hospital2 papers (2025–2025)David E. Neal · University of Oxford2 papers (2015–2019)Carlotta Palumbo · McGill University Health Centre2 papers (2025–2025) · 2 papers (2025–2025)Milan Hora · Institute of Medical Sciences2 papers (2025–2025)Saeed Dabestani · Lund University2 papers (2025–2025)Teele Kuusk · University of Cambridge2 papers (2025–2025)Tobias Klatte · Helios Hospital Bad Saarow2 papers (2025–2025)Stephanie E. Bonn · Karolinska Institutet2 papers (2025–2025)Alessandro Volpe · Università degli Studi del Piemonte Orientale “Amedeo Avogadro”2 papers (2025–2025)Patrick H. Maxwell · University of Cambridge2 papers (2016–2019)Umberto Capitanio · University of Bologna2 papers (2025–2025)Antonio Ramos‐Montoya · Cancer Research UK Cambridge Center2 papers (2015–2019)Lorenzo Marconi · St Thomas' Hospital2 papers (2025–2025)Eamonn R. Maher · Aston Medical (France)2 papers (2016–2017)